HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Indaptus Therapeutics, maintaining a price target of $12.
October 16, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Indaptus Therapeutics, maintaining a price target of $12.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Indaptus Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100